Breaking News

DeepSight ™ Technology Announces $25M Series A Funding Round
DeepSight ™ Technology has announced a $25 million Series A led by Deerfield Management Company, a healthcare investment firm, with additional funding from Wing, Alter Venture Partners, and Time BioVentures
“We are excited to be on the frontier of advancing medical imaging,” said founder and CEO Nader Sadrzadeh. “Based on internal studies, our technology has the potential to achieve 100 times greater sensitivity, ultimately allowing us to deliver better patient care.”
DeepSight is augmenting diagnostic medical imaging with the introduction of novel ultrasound technology, using patented hardware, software, and AI algorithms to deliver 100 times higher sensitivity than other ultrasound systems in the market. Existing ultrasound technologies are limited by sensitivity, depth penetration and clarity. DeepSight improves ultrasound image quality and more than doubles the effective range when compared to conventional technologies.
“DeepSight Technology provides a potential platform opportunity to enhance non-invasive and invasive medical imaging for multiple diagnostic procedures, and in turn, improve the patient care process with more efficacious testing that costs less,” said Steven Hochberg, Partner at Deerfield. “We are pleased to be leading this Series A financing in a novel medical device technology which has the potential to help advance a range of imaging procedures.”
People In This Post
Companies In This Post
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more